NCT01745120View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 8, 2018

Study Completion Date

February 21, 2018

Conditions
β-thalassemia Major
Interventions
GENETIC

LentiGlobin BB305 Drug Product

Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.

Trial Locations (6)

Unknown

Los Angeles

Oakland

Chicago

Philadelphia

Sydney

Bangkok

Sponsors
All Listed Sponsors
lead

Genetix Biotherapeutics Inc.

INDUSTRY

NCT01745120 - A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants | Biotech Hunter | Biotech Hunter